<?xml version='1.0' encoding='utf-8'?>
<document id="23381692"><sentence text="Clopidogrel, CYP2C19, and a Black Box."><entity charOffset="0-11" id="DDI-PubMed.23381692.s1.e0" text="Clopidogrel" /><entity charOffset="13-20" id="DDI-PubMed.23381692.s1.e1" text="CYP2C19" /><pair ddi="false" e1="DDI-PubMed.23381692.s1.e0" e2="DDI-PubMed.23381692.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23381692.s1.e0" e2="DDI-PubMed.23381692.s1.e1" /></sentence><sentence text="It has been presumed that CYP2C19 has a major role in the metabolism of clopidogrel"><entity charOffset="72-83" id="DDI-PubMed.23381692.s2.e0" text="clopidogrel" /></sentence><sentence text=" This presumption has been based on in vitro drug metabolism studies using microsomes from baculovirus infected insect cells (BD-Supersomesâ„¢)" /><sentence text=" If clopidogrel were primarily a CYP2C19 substrate, a drug/drug interaction with CYP2C19 inhibitors, such as proton pump inhibitors (PPIs), for example, omeprazole and lansoprazole would be anticipated"><entity charOffset="4-15" id="DDI-PubMed.23381692.s4.e0" text="clopidogrel" /><entity charOffset="153-163" id="DDI-PubMed.23381692.s4.e1" text="omeprazole" /><entity charOffset="168-180" id="DDI-PubMed.23381692.s4.e2" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.23381692.s4.e0" e2="DDI-PubMed.23381692.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23381692.s4.e0" e2="DDI-PubMed.23381692.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23381692.s4.e0" e2="DDI-PubMed.23381692.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23381692.s4.e1" e2="DDI-PubMed.23381692.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23381692.s4.e1" e2="DDI-PubMed.23381692.s4.e2" /></sentence><sentence text=" Several ex vivo studies, using ADP stimulated platelet aggregation, suggested that there was such an interaction" /><sentence text=" The data from these studies served as a basis for FDA to provide a &quot;Black Box&quot; warning for the clopidogrel label in March of 2010"><entity charOffset="96-107" id="DDI-PubMed.23381692.s6.e0" text="clopidogrel" /></sentence><sentence text=" However, a prospective clinical study, COGENT, and several large meta-analyses have failed to demonstrate a negative effect on major adverse cardiovascular events (MACE), with concomitant administration of clopidogrel and PPIs"><entity charOffset="207-218" id="DDI-PubMed.23381692.s7.e0" text="clopidogrel" /></sentence><sentence text=" The in vitro work using &quot;Supersomes&quot; was revisited" /><sentence text=" In vitro metabolism using hepatosomes, which resemble the native cytochrome P-450 enzyme expression, has confirmed the earlier work that clopidogrel is primarily a CYP3A substrate"><entity charOffset="138-149" id="DDI-PubMed.23381692.s9.e0" text="clopidogrel" /></sentence><sentence text=" This result correlates better with clinical findings" /><sentence text=" The absence of an increase in MACE by concomitant administration of PPIs, which are CYP2C19 inhibitors, to a regimen including clopidogrel, is therefore not surprising"><entity charOffset="128-139" id="DDI-PubMed.23381692.s11.e0" text="clopidogrel" /></sentence><sentence text=" A hypothesis is offered to explain why subjects, who carry two reduced function alleles of CYP2C19, may have more reactive platelets" /><sentence text="" /></document>